ID
15002
Description
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either pneumococcal vaccine or Prevenar™ in study 105553. Antibody persistence will be evaluated at 8-14 mo after completion of the 3-dose immunization course in study 105553. The immune response to a booster dose of GSK Biologicals' pneumococcal conjugate vaccine will also be evaluated when given at 12-18 mo to subjects not primed with GSK Biologicals' vaccine but with Prevenar™. The study has 3 groups. 1 group of children primed with GSK Biologicals' pneumococcal conjugate vaccine will receive a booster dose of the same vaccine. 2nd group of children primed with Prevenar™ will receive a booster dose of Prevenar™ (control group). 3rd group of children primed with Prevenar™ will receive a booster dose of GSK Biologicals' pneumococcal conjugate vaccine. All children will receive concomitantly a booster dose of DTPa-HBV-IPV/Hib vaccine. NCT00370396 Part: Non-Serious Adverse Events
Keywords
Versions (3)
- 5/9/16 5/9/16 -
- 5/9/16 5/9/16 -
- 5/11/16 5/11/16 -
Uploaded on
May 11, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Non-Serious Adverse Events Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine NCT00370396
Non-Serious Adverse Events "Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine" NCT00370396
Description
Non Serious Adverse Events
Alias
- UMLS CUI-1
- C0877248
Description
Non Serious Adverse Events: List
Alias
- UMLS CUI-1
- C0877248
Description
AE No.
Data type
boolean
Alias
- UMLS CUI [1]
- C0877248
Description
Description of Adverse Event
Data type
text
Alias
- UMLS CUI [1]
- C0877248
Description
Site of Adverse Event
Data type
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C1515974
Description
Start date
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C0808070
Description
Stop Date
Data type
date
Alias
- UMLS CUI [1]
- C0806020
Description
Start during immediate Post Vaccination Period
Data type
boolean
Alias
- UMLS CUI [1]
- C0205253
Description
Maximum Intensity:
Data type
integer
Alias
- UMLS CUI [1]
- C0518690
Description
Relationship to investigational products
Data type
text
Alias
- UMLS CUI [1,1]
- C0085978
- UMLS CUI [1,2]
- C0877248
Description
Outcome
Data type
integer
Alias
- UMLS CUI [1]
- C1705586
Description
(Refer to protocol for full definition.) If yes please specify type: HO: Hospitalisation ER: Emergency Room MD: Medical Personnel
Data type
boolean
Alias
- UMLS CUI [1]
- C0545082
Description
Medically Attended visit Specification
Data type
text
Alias
- UMLS CUI [1]
- C0018704
Similar models
Non-Serious Adverse Events "Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine" NCT00370396
C0805701 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,2])